Evidence-Based Treatments Modestly Improve Anhedonia in Depression
Key Clinical Summary
-
A meta-analysis of 22 randomized controlled trials (n=3,287) assessed treatments for depression and their effect on anhedonia.
-
Both psychotherapeutic and pharmacologic interventions showed small but significant improvement versus inactive controls (SMD = 0.26; 95% CI = 0.10–0.43).
- No differential efficacy observed between active NICE-recommended treatments; face-to-face therapy outperformed remote formats.
A systematic review and meta-analysis published in the Journal of Affective Disorders examined whether evidence-based treatments for depression effectively reduce anhedonia, defined as diminished interest or pleasure in activities. The research, drawing from multiple databases including Embase, Medline, and PsycINFO, highlights that while standard depression therapies help alleviate anhedonia, improvements are modest and require further optimization.
Study Findings
Researchers analyzed 22 randomized controlled trials comprising 27 comparisons and 3,287 adult participants. All included studies met National Institute for Health and Care Excellence (NICE) criteria for evidence-based psychotherapeutic or pharmacological depression treatments and used validated measures of anhedonia.
Across interventions, treatments produced a small but statistically significant effect on reducing anhedonia compared with inactive controls such as placebo, wait-list, or usual care (SMD = 0.26; 95% CI = 0.10–0.43; p = 0.004). However, when compared to active treatments already recommended by NICE guidelines, no differences emerged in efficacy between pharmacologic and psychotherapeutic modalities.
Analyses showed no moderation by study bias, treatment duration, or intensity. However, delivery format appeared to influence outcomes: face-to-face psychotherapy produced greater reductions in anhedonia than remotely delivered interventions (telephone or video).
Researchers concluded that while standard depression treatments confer some benefit for anhedonia, their effects are smaller than improvements observed for overall depressive symptoms in previous meta-analyses.
READ>>Digital Therapeutic Rejoyn May Aid Anxiety in MDD Patients
Clinical Implications
These findings suggest that current first-line depression treatments only partially address anhedonia, a core and disabling feature of depression associated with poorer functional outcomes and higher relapse risk.
For clinicians, this underscores the need to routinely measure anhedonia in depression management and treatment evaluation, rather than focusing solely on overall mood or symptom reduction. Given the limited effect size, integrating targeted strategies—such as behavioral activation, reward-processing interventions, or adjunctive pharmacologic agents—may enhance outcomes for patients with marked anhedonia.
The study also highlights potential limitations of remote care models for anhedonia, suggesting that in-person therapeutic engagement could be important for restoring reward sensitivity and emotional responsiveness.
Expert Commentary
“Treatments for depression were more efficacious at alleviating anhedonia relative to wait-list, placebo, or usual care,” wrote Daniel Pugh, CORE Data Lab, University College London, London, UK, and coauthors. “Given the significance of anhedonia in depression, future studies focused on optimizing treatment effects on anhedonia are required—it also needs to be routinely measured as a key outcome, in a consistent fashion.”
While existing depression therapies modestly improve anhedonia, the symptom remains under-addressed and insufficiently targeted. The authors call for consistent assessment and tailored interventions to better address this core feature of depressive disorders and enhance patient recovery outcomes.
